I. A. Libov

I. A. Libov

Auto-generated profile, based on publicly available information

I. A. Libov

Moscow Multidisciplinary Scientific and Clinical Center n.a. S.P. Botkin

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2022 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
ILI. A. Libov
I. A. Libov
YMYu. N. Moiseeva
Yu. N. Moiseeva
AKA. G. Komarova
A. G. Komarova
Hypertension (HTN) remains one of the most important risk factors for cardiovascular events. Modification of additional risk factors, along with a blood pressure decrease, significantly affects the risk of cardiovascular events. Hyperuricemia is one of the new factors that has a high prevalence in the population and affects the risk for cardiovascular events in hypertensive patients. In the treatment with fixed-dose combinations in patients with hypertension and hyperuricemia, metabolic neutrality is of particular importance. When prescribing diuretics, the practitioner faces additional difficulties. These drugs are highly synergistic when added to other major antihypertensives’ classes, but, in some cases, may worsen the metabolic profile. The use of the thiazide-like diuretic indapamide largely avoids a negative effect on the metabolic profile, making it the preferred choice for patients with hyperuricemia.

23 October 2024 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
AKA. I. Kirienko
A. I. Kirienko
SLS. G. Leontyev
S. G. Leontyev
Elena YarovayaElena Yarovaya
Elena Yarovaya
SKS. I. Konstantinov
S. I. Konstantinov
BOB. B. Orlov
B. B. Orlov
SMSergey Markin
Sergey Markin
Aim. To assess the safety and efficacy of a single intravenous bolus of non-immunogenic staphylokinase compared with alteplase in patients with massive pulmonary embolism and hemodynamic instability. Non-immunogenic staphylokinase is a modified recombinant staphylokinase with low immunogenicity, high thrombolytic activity and fibrin selectivity.Material and methods. This multicenter, open-label, randomized, comparative clinical trial FORPE in two parallel groups was conducted in 23 clinical centers in Russia. A total of 310 patients aged 18 years and older with hemodynamic instability and computed tomography pulmonary angiography verified massive pulmonary embolism and right ventricular dysfunction were included. The patients were randomly assigned in either non-immunogenic staphylokinase (15 mg) or alteplase (100 mg) group. Both medicines were administered intravenously. An independent biostatistician created a randomization sequence using computer-generated random numbers. Randomization was performed using the envelopes. The study was open-label, and emergency unit staff, investigators, and patients were informed about the assigned drug. The primary efficacy endpoint was 7-day all-cause death after randomization. The non-inferiority margin was set at 10% for the difference in 7-day all-cause mortality after randomization between the compared groups. Non-inferiority was tested using the Welch t-test for the primary efficacy endpoint. Secondary efficacy endpoints were analyzed in both the intention-to-treat and per-protocol populations.Results. Of 348 patients screened between December 25, 2020, and July 31, 2023, 310 (89%) were included in the study. Of the total number, 155 (50%) patients were randomized to the non-immunogenic staphylokinase group and 155 (50%) to the alteplase group. In the non-immunogenic staphylokinase group, the primary efficacy endpoint, 7-day all-cause death, was 2% in the intent-to-treat population and 2% in the per-protocol population, whereas in the alteplase group it was 3% (odds ratio (OR) 0,75, 95% confidence interval (CI) 0,11-4,49; p=1,00) and 3% (OR 0,75, 95% CI 0,11-4,52; p=1,00), respectively. The difference in the primary efficacy endpoint was 0,6% (95% CI -2,8 to -4,0) in the intent-to-treat population and 0,6% (95% CI -2,9 to -4,2) in the per-protocol population. Thus, the lower limit of the 95% CI did not cross the non-inferiority margin (p<0,001). There were no cases of hemorrhagic stroke in the non-immunogenic staphylokinase group, whereas there were three cases (2%) of hemorrhagic stroke in the alteplase group (p=0,25). Serious adverse events were experienced by 11 patients (7%) in the non-immunogenic staphylokinase group compared with 12 patients (8%) in the alteplase group (p=1,00).Conclusion. Non-immunogenic staphylokinase is at least as effective as alteplase in the treatment of patients with massive pulmonary embolism with hemodynamic instability and has a higher safety profile. Future observational studies of non-immunogenic staphylokinase are needed to continue assessing its safety and efficacy. Given the high safety and efficacy of non-immunogenic staphylokinase, its use should be studied in patients with moderate-to-high risk pulmonary embolism.

18 January 2024 in Medical alphabet
Verified
Journal Article
Closed access
PDF file
SBS. А. Bliznyuk
S. А. Bliznyuk
AKAnna Komarova
Anna Komarova
ILI. A. Libov
I. A. Libov
NLN. L. Lyakhova
N. L. Lyakhova
VAV. G. Alekseev
V. G. Alekseev
The purpose of this work is to increase the alertness of doctors treating cancer patients due to the high risk of developing acute coronary syndrome (ACS) and understanding the pathogenetic mechanisms of the development of ACS. Antitumor therapy should be personalized and agreed upon by an interdisciplinary team with an assessment of the impact on the risk of developing ACS, especially in patients with high cardiovascular risk. Given the limited number of studies, principles for the management of cancer patients with ACS should be based on an assessment of ischemic and hemorrhagic risks.

23 January 2025 in Medical alphabet
Verified
Journal Article
Closed access
PDF file
ILI. A. Libov
I. A. Libov
AKAnna Komarova
Anna Komarova
YMYu. N. Moiseeva
Yu. N. Moiseeva
SBS. A. Bliznyuk
S. A. Bliznyuk
NLN. L. Lyakhova
N. L. Lyakhova
VAV. G. Alekseev
V. G. Alekseev
The article presents an intriguing clinical case of myocarditis in a 36-year-old patient following severe sunburn. The disease developed with a pronounced pain syndrome, a significant increase in high-sensitivity troponin levels, and notable changes in the electrocardiogram (ECG). These factors complicated the differential diagnosis between acute coronary syndrome (myocardial infarction without coronary obstruction) and myocarditis. The rapid regression of clinical symptoms, normalization of myocardial injury biomarkers, atypical ECG dynamics for myocardial infarction, and the absence of coronary artery changes during angiography—alongside magnetic resonance imaging data revealing no areas of ischemic changes but showing inflammatory changes and myocardial edema—contributed to a diagnosis of myocarditis. Dynamic observation two months post-diagnosis indicated no deviations from standard indicators. The article also reviews literature on the mechanisms of myocardial damage associated with sunburn, which differ significantly from those seen in thermal and chemical burns. The authors suggest that severe sunburn is the most likely etiological factor for the observed damage, highlighting the potential for injury not only to the skin but also to internal organs.